```html

Sjögren's Syndrome – A Comprehensive Medical Guide

Overview

Sjögren’s syndrome (pronounced “shur‑g‑ren’s”) is a chronic, systemic autoimmune disease in which the body’s immune system mistakenly attacks the moisture‑producing glands, especially the salivary and lacrimal (tear) glands. This leads to dryness of the mouth and eyes, but the disorder can affect virtually any organ, including joints, lungs, kidneys, nerves, and skin.

Who it affects

• Women are disproportionately affected – about 9 times more women than men develop the condition.
• Typical age of onset is between 40 and 60 years, though it can appear in children or adolescents (<10 % of cases).
• It can occur as a primary disease (stand‑alone) or secondary to another autoimmune disorder such as rheumatoid arthritis or systemic lupus erythematosus.

Prevalence

• Estimated prevalence in the United States: 0.1 %–0.6 % of the population (≈ 300‑900 k people). [Mayo Clinic, 2023]
• Globally, prevalence ranges from 0.05 % to 4 % depending on the population studied and diagnostic criteria used. [WHO, 2022]

Symptoms

Symptoms can be variable and evolve over time. Below is a comprehensive list with brief explanations.

Classic (sicca) symptoms

• Dry eyes (keratoconjunctivitis sicca) – gritty, burning sensation; difficulty wearing contact lenses; increased risk of corneal ulcers.
• Dry mouth (xerostomia) – feeling of a cotton mouth, difficulty chewing, swallowing, or speaking; increased dental decay.

Oral and dental complications

• Dental caries, especially root caries.
• Oral candidiasis (thrush) due to reduced saliva.
• Sore or cracked tongue (glossitis) and burning mouth syndrome.

ENT and respiratory

• Hoarseness, chronic cough, or a sensation of a “lump in the throat.”
• Recurrent sinusitis, nasal crusting, or dry nose.

Musculoskeletal

• Joint pain, stiffness, or swelling (often symmetrical, resembling rheumatoid arthritis).
• Muscle aches and fatigue – reported by > 70 % of patients. [Cleveland Clinic, 2022]

Systemic manifestations

• Skin: dry, itchy skin; rash; Raynaud’s phenomenon.
• Peripheral neuropathy – tingling, numbness, or burning sensations in the hands/feet.
• Gastrointestinal: dysphagia, reflux, or inflammatory bowel disease‑like symptoms.
• Lung: interstitial lung disease, airway disease, or dry cough.
• Kidney: interstitial nephritis, tubular defects leading to electrolyte disturbances.
• Vascular: vasculitis causing palpable purpura, ulcers, or neuropathy.

Other notable features

• Parotid gland enlargement (often painless and bilateral).
• Increased risk of non‑Hodgkin’s lymphoma (especially marginal‑zone B‑cell lymphoma). [NIH, 2021]
• Fatigue and "brain fog" (difficulty concentrating, memory lapses).

Causes and Risk Factors

Sjögren’s syndrome is an autoimmune disorder, meaning the body’s immune system mistakenly attacks its own tissues. The exact trigger is unknown, but several factors appear to contribute.

Underlying mechanisms

• Genetic predisposition – Certain HLA alleles (e.g., HLA‑DR and HLA‑DQ) are more common in patients. [NIH, 2020]
• Environmental triggers – Viral infections (e.g., Epstein‑Barr virus, hepatitis C) have been implicated as potential initiators.
• Hormonal influences – The striking female predominance suggests estrogen‑related immune modulation.

Risk factors

• Female sex (9:1 ratio).
• Family history of autoimmune disease.
• Existing autoimmune disease (e.g., rheumatoid arthritis, lupus, scleroderma).
• Age > 40 (although pediatric cases exist).
• Certain viral exposures (e.g., hepatitis C).

Diagnosis

Because symptoms overlap with many other conditions, diagnosis relies on a combination of clinical assessment, laboratory tests, and imaging.

Clinical criteria

• American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2016 classification criteria – requires ≥4 points from items such as anti‑SSA/Ro antibodies, ocular staining score, focus score on minor salivary gland biopsy, and Schirmer’s test.

Key diagnostic tests

1. Schirmer’s test – strips of filter paper placed under the lower eyelid to measure tear production (≤5 mm in 5 min suggests dryness).
2. Ocular surface staining (fluorescein or lissamine green) – evaluates corneal and conjunctival damage.
3. Salivary flow measurement – sialometry quantifies unstimulated/stimulated saliva volume.
4. Minor salivary gland (labial) biopsy – histology shows focal lymphocytic sialadenitis with a focus score ≥1 (≥50 inflammatory cells per 4 mm²).
5. Serologic markers
   • Anti‑SSA/Ro (Ro‑52 and Ro‑60) – present in ~60‑70 % of patients.
   • Anti‑SSB/La – present in ~30‑40 %.
   • Rheumatoid factor (RF) and antinuclear antibodies (ANA) – often positive but non‑specific.
6. Imaging
   • Ultrasound or MRI of salivary glands – can detect glandular inflammation and atrophy.
   • Chest CT when pulmonary involvement is suspected.
7. Additional labs for systemic involvement – CBC, ESR/CRP, renal function, complement levels, vitamin D.

Differential diagnosis

• Age‑related dry eye (dry eye syndrome).
• Medication‑induced xerostomia (e.g., antihistamines, antidepressants).
• Sarcoidosis, amyloidosis, graft‑versus‑host disease.
• Secondary causes (e.g., hepatitis C infection).

Treatment Options

There is no cure, but treatment focuses on relieving symptoms, preventing complications, and managing systemic disease.

1. Symptom‑directed therapies

• Dry eyes
  • Artificial tears (preservative‑free) – 4–6 times daily.
  • Ocular lubricating ointments at night.
  • Ciclosporin 0.05 % ophthalmic emulsion (Restasis) or lifitegrast 5 % (Xiidra) for moderate‑to‑severe disease.
  • Punctal plugs to reduce tear drainage.
• Dry mouth
  • Saliva substitutes (sprays, lozenges).
  • Prescription salivary stimulants – pilocarpine 5 mg PO TID or cevimeline 30 mg PO TID.
  • Good oral hygiene: fluoride toothpaste, fluoride rinse, sugar‑free gum.
• Joint and muscle pain
  • Acetaminophen or NSAIDs (ibuprofen, naproxen) as needed.
  • Low‑dose glucocorticoids for short‑term flares.

2. Disease‑modifying systemic agents

Medication	Typical Indication	Key Considerations
Hydroxychloroquine (Plaquenil)	Mild‑moderate systemic disease, arthralgia, fatigue	Baseline & annual ophthalmologic exam; monitor retinal toxicity.
Low‑dose oral prednisone	Active systemic inflammation	Limit to <10 mg/day; taper to avoid long‑term adverse effects.
Immunosuppressants (methotrexate, azathioprine, mycophenolate)	Severe organ involvement (lung, kidney, vasculitis)	Requires regular CBC, liver/kidney labs.
Biologic agents (rituximab, belimumab)	Refractory disease, lymphoma‑related manifestations	Infusion reactions; screen for hepatitis B/C, TB.

3. Management of complications

• Dental care – routine dental check‑ups every 3‑6 months, fluoride treatments, and possible daily chlorhexidine mouthwash.
• Vaccinations – annual influenza, COVID‑19 boosters, pneumococcal vaccine (especially for immunosuppressed patients).
• Regular cancer surveillance – physical exam and prompt evaluation of persistent glandular swelling; consider ultrasound if lymphadenopathy present.

4. Lifestyle and supportive measures

• Stay hydrated (minimum 2 L water/day).
• Use a humidifier at night to alleviate airway dryness.
• Avoid alcohol, caffeine, and tobacco – all worsen dryness.
• Practice good oral hygiene (soft toothbrush, fluoride toothpaste).
• Protect eyes from wind, smoke, and air‑conditioning; wear sunglasses.

Living with Sjögren's Syndrome

Effective self‑management can dramatically improve quality of life.

Daily habits

• Eye care – keep artificial tears in multiple locations (home, work, car); use eye masks at night if dryness is severe.
• Oral care – sip water frequently; chew sugar‑free gum to stimulate saliva; schedule dental cleanings every 6 months.
• Nutrition – favor moist, soft foods; avoid overly salty or dry snacks; include omega‑3 rich fish to support anti‑inflammatory pathways.
• Physical activity – low‑impact exercises (walking, swimming, yoga) reduce fatigue and improve joint health.

Psychosocial support

• Join patient support groups (e.g., Sjögren’s Foundation). Connecting with others reduces isolation.
• Consider counseling or cognitive‑behavioral therapy for chronic pain and fatigue.
• Keep a symptom diary – helps clinicians adjust therapy and identifies triggers.

Monitoring

• Annual rheumatology visit with labs (CBC, ESR/CRP, renal & liver panels, autoantibodies).
• Dental exam every 6 months.
• Ophthalmology exam at least once per year, or sooner if symptoms worsen.

Prevention

Because the exact cause is unknown, primary prevention is not possible. However, risk reduction strategies focus on modifiable factors and early detection.

• Prompt treatment of viral infections (e.g., hepatitis C) that have been linked to secondary Sjögren’s‑like disease.
• Avoid medications that cause dry mouth/eyes when alternatives exist (anticholinergics, certain antihistamines).
• Maintain a healthy immune system – balanced diet, regular exercise, adequate sleep, and stress management.
• Early screening for autoimmune disease in individuals with a strong family history can lead to earlier diagnosis and treatment.

Complications

If left untreated or inadequately controlled, Sjögren’s syndrome can lead to serious health problems.

• Dental decay and oral infections – up to 80 % develop caries; may require extractions or prosthetic replacements.
• Corneal ulceration or vision loss – severe keratitis can scar the cornea.
• Systemic organ involvement – interstitial lung disease, renal tubular acidosis, peripheral neuropathy.
• Lymphoma – risk of non‑Hodgkin’s B‑cell lymphoma is 5‑ to 10‑fold higher than the general population. [NIH, 2021]
• Vasculitis – can cause skin ulcers, peripheral nerve damage, or organ infarction.
• Chronic fatigue syndrome – profound, persistent fatigue that interferes with daily activities.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Sjögren’s syndrome.” 2023; CDC. “Autoimmune diseases.” 2022; NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Sjögren’s syndrome.” 2021‑2024; WHO. “Global prevalence of autoimmune diseases.” 2022; Cleveland Clinic. “Sjögren’s syndrome overview.” 2022; ACR/EULAR Classification Criteria for Sjögren’s Syndrome, 2016.

```